Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.

出版年份 2022 全文链接

标题

作者

关键词

出版物

JOURNAL OF CLINICAL ONCOLOGY

Volume 40, Issue 16_suppl, Pages 3510-3510

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2022-06-07

DOI

10.1200/jco.2022.40.16_suppl.3510

向作者/读者发起求助以获取更多资源

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

JOURNAL OF CLINICAL ONCOLOGY

向作者/读者发起求助以获取更多资源

Protocol

Reagent

Reprint

Find Funding. Review Successful Grants.

Ask a Question. Answer a Question.